CRISPR Therapeutics AG (CRSP) SEC Filings & Earnings Calls

Reimbursement and access risk for CASGEVY globally

“Efforts underway with government and reimbursement authorities globally to ensure sustainable access.”

Dependence on Vertex collaboration

“Collaboration expense, net, was $40.3 million for the three months ended June 30, 2026, compared to $45.2 million for the three months ended June 30, 2025.” · word for word

History of losses and need for additional capital

“We have a history of recurring losses and expect to continue to incur losses for the foreseeable future... we will need additional capital to fund our operations.” · word for word

Clinical and regulatory uncertainty

“Most of our programs are still in early stages of research and development and the outcome of our efforts is uncertain.” · word for word

Dependence on CASGEVY commercialization

“We have not generated any revenue to date from sales of any wholly-owned product and do not expect to do so in the near future.” · word for word

Need for additional capital

“We anticipate that we will continue to incur losses for at least the next several years.” · word for word

Clinical trial risk

“Most of our programs are still in early stages of research and development and the outcome of our efforts is uncertain” · word for word

Dependence on CASGEVY commercial success

“CASGEVY is the only approved product; revenue concentration.”

Clinical trial risks for pipeline programs

“Multiple programs in early stages; regulatory and clinical uncertainties.”

Share dilution from capital band increase

“the Board of Directors proposes to amend and restate art. 3a para. 1 of the Articles of Association to increase the capital band of the Company to the upper limit of CHF 3,521,838.51 by authorizing the Board of Directors to issue a corresponding number of common shares, which as of March 31, 2026 corresponds to up to 18,795,173 of our common shares and repre” · word for word

Share dilution from conditional share capital increase

“The Board of Directors proposes to increase the conditional share capital for the conversion of bonds and similar debt instruments under our Articles of Association from 8,202,832 shares to 9,366,947 shares.” · word for word

Low say-on-pay support

“approximately 71% of the votes cast on our SEC say-on-pay proposal expressed support for the compensation program offered to our NEOs as disclosed in last year's proxy statement.” · word for word

Potential dilution from convertible notes; up to ~11.4M shares if fully converted.

“Initially, a maximum of 11,363,580 Common Shares may be delivered upon conversion of the Notes.” · word for word

Convertible notes may dilute equity upon conversion; high debt level for a pre-commercial biotech.

“convertible senior notes due 2031; aggregate principal amount of $550 million”

Operating Losses

“We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future.” · word for word

Funding Need

“We will need to raise substantial additional funding, which will dilute our shareholders.” · word for word

Competition

“We face significant competition in the biotechnology and pharmaceutical industries.” · word for word

Net loss continues

“Net loss for Q4 and FY not explicitly stated in excerpt but implied by business update; typical for biotech.”

Dependence on CASGEVY commercial success

“Revenue concentrated in one product; pipeline still clinical.”

Clinical trial risks; forward-looking statements subject to uncertainties.

“Risks and uncertainties discussed under Risk Factors”

Recurring losses and negative cash flow

“We have a history of recurring losses and expect to continue to incur losses for the foreseeable future” · word for word

Dependence on Vertex collaboration for CASGEVY

“CASGEVY is the first therapy to emerge from our strategic partnership with Vertex and is being advanced under a joint development and commercialization agreement between us and Vertex” · word for word

No product revenue from wholly-owned products

“We have not generated any revenue to date from sales of any wholly-owned product and do not expect to do so in the near future” · word for word

Dilution risk from ATM offerings

“To the extent that we raise additional capital through the future sale of equity or debt securities, the ownership interests of our shareholders will be diluted” · word for word

Clinical and regulatory uncertainty

“Most of our programs are still in early stages of research and development and the outcome of our efforts is uncertain” · word for word